T cells from HLA-Ar healthy donors were co-cultured with autologous dendritic cells (DC) loaded with apoptotic tumor cells expressing rat neu, and were induced to mature by tumor necrosis factor (TNF)a. and interleukin (IL)-l~(mDC'ren) or by the CCL16 chemokine (CCL16/mDCnen). Priming by CCL16/mDCnet, induces a larger population of T cells that express cytoplasmatic interferon (IFN)y, TNFa., perforin and granzyme B compared to those primed by mDC,ren. T cells primed by CCL16/ mDCnen release IFNy in response to human HER-r cells and kill human HER-r target cells more efficiently than those primed by mDC"et,. Our results show that both the loading of DC with xenogeneic rat neu and their maturation by CCL16 are two issues of critical importance for the elicitation of an effective response to human HER-2 in T cells from normal donors.
Most human tumor antigens are non-mutated self proteins that are either overexpressed by tumors or developmentally regulated (1). HER-2 is of especial interest on account of its overexpression in breast, ovary, uterus, lung, kidney, stomach, and pancreas carcinomas (2) . It is a l85-kDa transmembrane glycoprotein with tyrosine kinase activity and homology to the epidermal growth factor receptor (3) . The HER-2 gene is present as a single copy in normal cells and often amplified in cancer cells (4) (5) .
Several immunogenic HER-2 peptides recognized by cytotoxic T lymphocytes or helperTcells (Th) have been identified (6) . Various protocols for generating specific T cell-mediated immune responses to these peptides have been examined in pre-clinical models (7) and in clinical trials (8) (9) . Vaccines based on HER-2 peptides inhibit experimental tumor growth (7) . In humans, no significant cure has been reported, though an immunological response is raised against the peptides used for vaccination (10) . The principal limit of these vaccines is that is a self-antigen, and thus peptides are not able to overcome tolerance and mount an effective immune reaction. Studies with transgenic mouse models show that tolerance to HER-2 deletes and inactivates T cells interacting' with high avidity against it (11), whereas low avidity T cells are still present. These cells can be activated and expanded to elicit a protective antitumor response (12) (13) .
To break tolerance towards human HER-2, considerable success has been achieved by using heteroclitic or xenogeneic peptides (14) (15) (16) (17) . Xenogeneic determinants activate Th cells that then cooperate with B cells to elicit a high-affinity antibody response against self-determinants. In addition, the xenogeneic protein may display critical amino acid substitutions that trigger cross-reactive and low-affinity T cell clones. The cytokines released by T cells reacting to foreign determinant help the immune recognition of self-antigens in a paracrine way.
In the present work we assess the ability of the CCL16 chemokine to enhance the antigenpresenting capacity of dendritic cells (DC) loaded with apoptotic cells expressing rat neu to autologous T cells from healthy donors. The homology of the amino acid sequence of rat neu and human HER-2 is 88% (18) . Moreover, in both mouse (19) and humans (20) we have previously shown that CCL 16 powerfully triggers effector and antigen-presenting functions of macrophages and enhances T cell effector activity. Induction of the maturation of human monocyte-derived DC is indeed an important mechanism whereby CCL 16 directly regulates their ability to prime T cell responses (20) .
Our results indicate that both strategies are of critical importance in the elicitation of marked T helper and cytotoxic responses against human HER-2.
MATERIALS AND METHODS

Cell lines
The murine N202. IA cell clone used to load DC was originally derived from a mammary carcinoma of an FVB-neuN mouse (H-2 q ) transgenic for the rat neu proto-oncogene, kindly provided by P.L. Lollini, Istituto CanceroI., Bologna University, Italy. Human tumor cells used as targets for HER-2 specific cytotoxic T cells were the HER-2+CFPAC-I (human pancreatic adenocarcinoma cells, American Type Culture Collection -ATCC-number CRL-1918™, HLA-A*0201+) and the HER-2-Jurkat (human T lymphoblastoma cells, ATCC number TIB-152™, HLA-A*020 I"). The level of HER-2 expression by these lines was assessed by flow cytometry using the 7. I6.4 monoclonal antibody (MoAb) Ab-4 or Ta-I MoAb Ab-5 (Oncogene Res Prod, Calbiochem, Cambridge, MA) for rat neu or human HER-2 respectively. Tumor cells were cultured in plastic flasks (BD Falcon, Bedford, MA) under standard conditions (37 QC, 5% CO 2 in a fully humidified atmosphere) using RPMI 1640 (Bio Whittaker Europe, Vervies, Belgium) supplemented with 10% heat-inactivated Fetal Bovine Serum (FBS) (Bio Whittaker Europe) for CFPAC-l and Jurkat or DMEM (Bio Whittaker Europe) supplemented with 20% heatinactivated FBS for N202.IA. Cells were detached from the plastic with a 0.25% trypsin-EDTA solution (Sigma Aldrich, St. Louis, MO). The cultures were routinely tested and found free from Mycoplasma contamination.
Transfection ofJurkat cells
FuGene 6 (Roche Diagnostics, Laval, QC, Canada) was used to transfect Jurkat cells with plasmid coding for human EC-TM domains of trasforming human HER-2, according to the manufacturer's recommendations. The sequence for the EC-TM domains of trasforming human HER-2 was cloned into the multiple cloning site of the pcDNA3. I expression vector (Invitrogen, San Diego, CA), containing the neomycin resistance gene. Restriction analysis of the human HER-2 cDNA sequence indicates that there is a single restriction site for AccIII about 20 bp (2045 nt) after the end of the sequence encoding the TM domain. For this reason, pcDNA3.Ihuman HER-2 plasmid was digested with AccIII and XbaI restriction enzymes to eliminate the sequence encoding the intracellular domain of human HER-2. The cut plasmid was ligated with one synthetic double-strand oligonucleotide containing the TAAtranslation stop signal triplette. Transfected cells were cultured in RPMI 1640 (Bio Whittaker Europe) supplemented with 10% heatinactivated FBS (Bio Whittaker Europe) and I mglmlof geneticin (G418, Sigma Aldrich). Their HER-2 expression was assessed by flow cytometry using Ta-l MoAb Ab-5 for human HER-2. To obtain stable transfectants highly expressing transgene, positive cells were enriched by cell sorting with a fluorescence-activated MoFIo High-Performance Cell Sorter (DakoCytomation, HeverIee, Belgium). These cells were called Jurkat HU.
Apoptosis induction
Rat neu-expressing N202.1A cells, cultured in RPMI 1640 without phenol red (Bio Whittaker Europe) supplemented with 10% heat-inactivated certified FBS (Invitrogen Life Technologies, Grand Island, NY), were irradiated with 1500 flW/cm 2 ultraviolet Blight (UVB; 6W, Vilber Lounnat, Mamee La Vallee, France) for 30 min. Apoptosis was detected by staining with the phycoerythrin (PE)-conjugated Annexin V Apoptosis Detection Kit I (BD Biosciences) and by flow cytometry after 24 and 48 hrs of incubation in complete medium.
Generation. loading and maturation ofDC
Human peripheral blood mononuclear cells (PBMC) were obtained from buffy coat preparations of HLA-A2+ healthy donors by sedimentation over Ficoll-Hystopaque" (Amersham Pharmacia, Uppsala, Sweden) and cryopreserved in FBS supplemented with 10% dimethyl sulfoxyde (DMSO) (Sigma Aldrich) in liquid nitrogen. CDI4+ cells were isolated by positive immunoselection with magnetic beads (Miltenyi Biotec, Bergisch Gladbach, Germany). The resulting preparations were consistently > 95% CDI4+, as determined by FACSCalibur (BD Biosciences, San Diego, CA). Immature DC (iDC) were generated in 6-well plates by culturing 5 x 10 6 CD14+ cells in 3 ml RPMI 1640 medium (Bio Whittaker Europe) supplemented with 10% heat-inactivated certified FBS, 100 ng/ml of granulocyte/macrophage colony-stimulating factor (GM-CSF) and 50 ng/ml ofinterleukin (IL)-4 (both from PeproTech, London, UK). On day 3, two-thirds of the medium were replaced by fresh medium containing GM-CSF and IL-4. On day 6, cells were harvested, resuspended as 1 x 10 6 cells/ml of RPMI 1640 medium supplemented with 10% certified FBS and loaded with N202.1A apoptotic tumor cells overnight at 1:1 ratio DC:tumor cell. Maturation of DC pulsed with rat neu' apoptotic cells was induced by the addition of 50 ng/ml tumor necrosis factor (TNF)a and 50 ng/ml IL-l13 (both PeproTech) (mDC"eU) or 100 ng/ml of recombinant CCL16 13-chemokine (PeproTech) (CCL16/mDC"el/) for a further 24 hrs. The phenotype of both iDC and mature DC (mDC) was analysed by flow cytometry to evaluate the complete down-regulation of CD14, the high expression of CDla and the percentage of expression of major histocompatibility complex (MHC) class II, CD83, CD80 and CD86.
N202.1A cell uptake by iDC
To assess the uptake of apototic N202.lA cells by iDC, lOx 10 6 N202.lA cells were stained green with 5 M lipophilic fluorochrome 5,6-carboxyfluorescein diacetate succinimidyl ester (CFSE, Molecular Probes, Poorgebouw, The Netherlands) for 5 min at room temperature (RT) in the dark in phosphate buffered saline (PBS) (Bio Whittaker Europe) and washed four times in complete medium before induction of apoptosis. 48 hrs after apoptosis, they were co-cultured with DC at 1:1 ratio DC:tumor cell. The cells were harvested 4-18 hrs later, and DC were stained with PE-conjugated anti-human CDla MoAb (Serotec, Oxford, UK). Flow cytometry was performed to determine the percentage of cells that phagocytosed apoptotic tumor cells, based on the number of double-positive cells (green! red). To prepare cells for confocal microscopy, harvested cells were fixed and DC were stained with PE-conjugated anti-human CDla MoAb. Nuclei were stained with 300 ng/ml Hoechst Blue (Sigma Aldrich). Cells were then centrifuged with a cytospin (Shandon, Italscientifica, Genova, Italy) (600 rpm for 4 min) and coverslips were mounted on a glass slide with Mowiol (Sigma Aldrich) and viewed with a Leica TCS SP2 laser scanning confocal microscopy driven by Leica Confocal Software. The images were acquired at RT by means of 63x/1.32 N.A. PL APO objective at 1024xl024 pixel resolution (Leica Lasertechnik, Heidelberg, Germany). Images were recorded as TIF files and processed (Adobe Photoshop, Mountain View, CA) to subtract background and enhance lower and middle intensity fluorescence.
T cell-DC cocultures
T cells were purified on a nylon wool column (Robbins Scientific Corporation, Sunnyvale, CA) and stimulated at 20: 1 ratio with autologous DC that had ingested apoptotic rat neu expressing tumor cells and were then matured with different stimuli. They were co-cultured in RPMI 1640 supplemented with 10% heat-inactivated certified FBS. At days 7 and 14, T cells were re-stimulated with new loaded-DC and cultured until day 21. On days 3 and 5 of each re-stimulation one-third of the medium was replaced by fresh culture medium supplemented with 20 lU/ml of IL-2 (PeproTech). Responses of T cells to autologous apoptotic HER-2+cells loaded-DC or whole HER-2+cells and unloaded DC or HER-2-cells were tested in 24 hrs interferon (IFN)y ELISpot or in 4 hrs cytotoxicity assays.
Flow cytometry
Cells were analysed by multicolour flow cytometry with a BD Biosciences FACSCalibur cytometer running CellQuest analysis software (BD Biosciences). Cells recovered were washed and re-suspended in PBS supplemented with 0.2% bovine serum albumin (BSA) and 0.01% sodium azide. Non-specific sites were blocked with rabbit IgG (Sigma Aldrich). DC phenotype was characterised by staining cells for 20 min at 4°C with MoAb against PE-conjugated anti-human CD la (Serotec), fluorescein isothiocyanate (FITC)-conjugated anti-human CD14, PE-conjugated anti-human CD83, anti-human CD80, anti-human CD86 (all from BD Biosciences) and FITC-conjugated anti-human MHC class II (Ancell Corporation, Bayport, MN). Cells were gated according to their light-scattering properties to exclude cell debris and contaminating lymphocytes, and according to their propidium iodide negativity (Sigma-Aldrich) to exclude dead cells. For the detection of intracellular IFNy, IL-4, TNFa, cells were incubated with monensin (2 J-lM) (Sigma Aldrich) during the last 4 hrs before harvest in the presence of anti-CD3 coated MoAb (OKT3, 10 ug/rnl), Cytoplasmic expression of perforin and granzyme B was evaluated in 4 hr monensin-treated T cells without additional stimulation. Recovered T cells were fixed with paraphormaldeide (2%), permeabilized with saponin (5%) and stained with MoAb against FITC-conjugated antihuman CD4 (Dako Cytomation), peridinin-chlorophilleprotein Complex (PerCP)-conjugated anti-human CD8, allophycocyanin (APC)-conjugated anti-human IFNy, PE-conjugated anti-human IL-4, anti-human TNFa, FITC-conjugated anti-human granzyme B (all from BD Biosciences) and PE-conjugated anti-human perforin (Ancell Corporation). Isotype-matched IgG used as negative controls were from Dako Cytomation.
IFNy ELISpot Assay
For the ELISpot assay, wells of 96-well plates with nitrocellulose membrane inserts (Millipore, Bedford, MA) were coated with 100 ul of primary anti-human IFNy MoAb solution (5 ug/ml in PBS) (Endogen, Woburn, MA) and incubated overnight at 4°C. The plates were then washed four time with PBS, and 200 ul of PBS supplemented with 4% BSA were added for 1-2 hrs to block non-specific binding. Next, 2.5 x 10 4 to 5 x 10 4 responder T cells at 10:1 ratio with stimulator cells (unloaded or human HER-2+ tumor cells loaded-DC or whole human HER-2+ 1 -tumor cells) were added in a final volume of 100 ul of AIM-V medium (Gibco, Invitrogen Life Technologies). The assay was performed in quadruplicate wells for each experimental condition. The cultures were then incubated in a humidified atmosphere of 5% C02 in air at 37°C for 24 hrs. Cells were removed by washing the plates four times with PBS and four times with PBS supplemented with 0.05% Tween 20 (Sigma Aldrich) (wash buffer). Then 100~l of biotinylated secondary anti-IFNy MoAb (1 ug/ml in PBS/4% BSA) (Endogen) were added to each well. The plates were again incubated in a humidified atmosphere of 5% CO 2 in air at 37°C for 2 hrs. The washing steps were repeated, and after a 30 min incubation at RT with horseradish peroxidase (HRP) conjugated-Streptavidin (100 ul/well of 1:1000 dilution in wash buffer) (Endogen), the plates were washed again four times with wash buffer. 100 ul of substrate (AEC Staining Kit, Sigma Aldrich) were added to each well to develop the spots. The reaction was stopped after 5-10 min under running tap water and the membrane was left to dry in the dark. The spots were counted by computer-assisted image analysis (Transtec 1300 ELISpot Reader, Nanogen, Buttigliera Alta, Turin, Italy). In some experiments, co-cultured T cells were enriched in CD8+ or CD4+ cells by positive immunoselection with magnetic beads (Miltenyi Biotec) according to the manufacturer's recommendations. The purity of selected CD8+ or CD4+ cell fractions was> 95%, as detected by flow cytometry. For blocking experiments, target cells were pre-incubated with anti-HLA I MoAb (w6/32, 30 ng/ml) (Serotec) for 15 min at 4°C. As positive controls, some T cells were incubated with phorbol 12-myristate 13-acetate (PMA; 10 ng/ml) (Sigma Aldrich) and ionomycin (500 ng/ml) (Sigma Aldrich) in the ELISpot plate (data not shown). In each experiment, the mean number ± SEM of spots in quadruplicate control wells (unloaded DC or T cells in medium only) was always subtracted from the mean number ± SEM of spots in quadruplicate experimental wells.
Cytotoxicity Assay
The 51Cr-release assay was performed at 20:1, 10:1, 5:1 and 2.5:1 Effector to Target ratios. Briefly, targets (unloaded or human HER-2+ tumor cells loaded-DC or whole human HER-2+ 1 -tumor cells) were labeled with 51Cr sodium chromate (PerkinElmer Life Sciences, Zaventem, Belgium) for 1 hr at 37°C, washed twice and added to wells of 96-well plates (5 x 10 3 cells/well) with effector T cells. The assays were performed in triplicate in a final volume of 200 ul of RPMI 1640 supplemented with 10% heat-inactivated certified FBS. After 4 hrs incubation, 50~l of supernatant were collected on Lumaplate (PerkinElmer Life Sciences), and radioactivity was measured with a Top Count Microplate Scintillation Counter (Packard Biosciences B.Y., Graningen, The Netherlands). Values were expressed as percentages of specific lysis, and LV)10 7 effector cells were calculated as previously described (19) . The percentage of specific lysis was calculated according to the formula: % specific lysis = (experimental cpm -spontaneus cpm)/(maximal cpm -spontaneus cpm) X 100. Spontaneous release was always < 20% of maximal release.
Statistical Analysis
An unpaired two-tailed Student's ttest (GraphPadPrism 4, GraphPad Software, San Diego, CA) was used for statistical analysis of the experiments with p <0.05 as the significance cut-off.
RESULTS
Generation of iDC and phagocytosis of apoptotic N202.1A cells
We first investigated the ability of iDC to phagocytose apoptotic N202.1A tumor cells expressing rat neu. iDC were prepared from CD14+ cells in the presence ofIL-4 and GM-CSF. When the generation of iDCs was assessed by flow cytometry, the cells recovered displayed the characteristic phenotype of iDC with high expression of CD 1a and MHC class II, and low or no expression of CD 14, CD83, CD80 and CD86 (Fig. 1 A) . For induction of apoptosis, CFSE-labelled N202.1A cells were exposed to UV-B light for 30 min. The cells recovered displayed typical morphological features of apoptosis: chromatin condensation and fragmentation of cell nuclei into apoptotic bodies (data not shown). After 24 hrs UV-B exposure cells were stained with PE-conjugated Annexin V and examined by flow cytometry: 78% of them were Annexin-V+. This positivity increased to over 90% in those recovered after 48 hrs (Fig. 2) and they were used to load iOe.
To study the uptake of apoptotic tumor cells by iOC, N202.IA cells were stained with CFSE before induction ofapoptosis ( Fig. 3 B) . Apoptotic cells were then co-incubated with iOC for different times to determine the optimal conditions for internalization. iDC labelled in red with PE-conjugated anti-CD Ia MoAb (Fig. 3 A) ingested apoptotic tumor cells after only 4 hrs of co-incubat ion (data not shown), while 18 hrs later virtually all CD Ia' cells showed green CFSE staining (Fig. 3 C) . Confocal microscopy showed phagocytosed apoptotic N202.1A cells inside or in the process of being phagocytosed by iDC ( Fig. 3 0, E) .
Following overnight antigen loading, DC were matured for 24 hrs in the presence of TNFa and IL-IP (mDCn,") or the CCLl6 chemokine (CCLl6/ mOCn,"). Flow cytometry confirmed that both treatments upregulated C083, and the co-stimulatory molecules C080 and C086, in compliance with a mature OC phenotype (Fig. I B, C ).
CCLl 6/mD~" elicits a stronger ThI and cytotoxic response
T cells were cultured for one week with autologous mOCn,1I or CCL 16/mOCnell, and the intracellular presence of IFNy, TNFa. and IL-4 was evaluated by flow cytometry on recovered CD8and C04+T cells. While T cells cultured with both mDCn.1I and CCL 16/mDC"" "display intracytoplasmi c IFNy, TNFa, perforin and granzyme B (Fig. 4  A-D) , IL-4 production was not evident (data not shown). Interestingly, in the cultures stimulated by *, percentage ofpositive cells from co-culture with CCL16/mDCnf!ll significantly higher (p<0.05) than that with mDC"'"'.
cells producing IFNy and perforin was significantly higher.
mDCnell and CCL16/mDCnell prime T cells to respond to human HER-2
To evaluate whether DC loaded with rat neu apoptotic cells prime a T cell response to human HER-2, T cells from HLA-A2+ normal donors (n=4) were first cultured with autologous mDCnell or CCL l6/mDCnell for 7 or 21 days and then triggered with autologous DC loaded with human HER-2+ CFPAC-l tumor cells in an ELI Spot assay ( Fig. 5 A) . An increased number of IFNy secreting-T cells was always observed in T cells primed by CCL 16/mDCnell in comparison to those from mDCnell.
Similar results were obtained when whole human HER-2+ expressing tumor cells, CFPAC-l or Jurkat cells transfected with a plasmid coding for human HER-2 (Jurkat HU), were used as targets in the ELISpot assay with T cells recovered after 7 and 21 days ( Fig. 5 B, C) . Blocking experiments with anti-Hl.A I MoAb showed that CD8+ T cells are activated against human HER-2+ targets by mDCnell ( Fig. 5 D, E) both after 7 and 21 days. However CCL 16/mDCnell are more effective in cross-priming autologous T cells against human HER-2+ targets. In fact a higher number of CD8 IFNy secreting-T cells seems to be involved in this enhanced response as suggested by the strong reduction in the number of spots in the presence of anti.HLA I MoAb (from 55 to 6 spots /5xl0 4T cells and from 146 to 82 spots/Sx IO"T cells after 7 and 21 days of co-culture, respectively). We also evaluated the ability of purified CD8 +and CD4+ T cells, recovered after 21 days' stimulation with mDCneu or CCL l6/mDCnerl, to recognize human HER-2 target. When they were seeded on the El.fSpot plate with human CFPAC-l tumor cell loaded with autologous DC, both produced IFNy, however, higher numbers of CD8 +and CD4 +T cells secreting IFNy in response to human HER-2 were again observed in the cultures primed by CCL 16/ mDCneu (Fig. 5 F) .
mDCneu and CCL 16/mDC'ell prime a T cyto tox ic response to human HER-2+targets
To evaluate the ir ability to specifically kill human HER-2 +loaded-DC or whole human HER-2 + tumor cells, T cells primed with mDCm'" and e CL16/ mDCm'u and recovered after 2 1 days co-culture were tested in a 4 hr 51Cr release assay. A significant specific cytolytic activity aga inst human CFPAC-1 loaded-autologous DC and Jurkat HU cells was evident ( Fig. 6 A, B) . In both cases, cultures primed by CCL 16/mDC1Jetl displayed a stronger cytol ytic activity than those primed by mDCneli. When cytotoxicity data were transformed into LU, it was evident that priming by CCL16/mDCnell significantly increased the cytotoxic activity generated in these cultures.
DISCUSSION
MoAb against HER-2 are now commonly employed in clinical practice and several forms of vaccine are being investigated. HER-2 vaccines may provide a long-term control oftumor progression (21) and lead to tumor cure in the absence of unwanted side-effects (22). The use of DC loaded with tumorassociated antigen seems a very promising anti-tumor vaccination strategy (23) . In this case, two critical issues are the choice of the antigen to load DC and the cytokine cocktail to induce DC maturation. In the present study, DC were loaded with apoptotic tumor cells expressing the rat ortholog ofHER-2, and their maturation was induced by the CCL 16 chemokine. Both issues proved of major importance for the elicitation of marked and specific immune response to human HER-2 in T cells from normal donors.
These data show that iDC efficiently take up apoptotic rat neu' N202.IA tumor cells. Both conventional TNFa + IL-ll3 and CCL16 induce maturation of loaded iDCneli without difference in phenotype. Both mDCneli and CCL16/mDCncli primed T cells from normal donor to specifically release IFNy when triggered by human HER-2. However, a larger number of T cells that produce IFNy and express perforin and granzyme B were recovered from co-culture with CCL16/mDCneli in comparison to those co-cultured with mDCneli.
While the priming of naive T cells with mDCncli results in the generation of a strong response to HER-2, a higher number of IFNy secreting-T cells was recovered following CCL16/mDCncli priming. Blocking experiments with anti-HLA I MoAb demonstrate that CD8+ T cells are primed in both co-cultures. However, CCL 16/mDCneli are more effective in cross-priming autologous CD8+ T cells. Peptides from phagocytosed apoptotic cells are mostly presented by HLA II molecules and partially cross-presented by HLA I (24) . Nevertheless, efficient cross-priming of a CD8+ T cell cytotoxic response has been shown when DC are loaded with apoptotic tumor cells (25) (26) (27) .
Priming with DCneli induces the generation of a cytotoxic response specific for human HER-2+ target cells. Both DC loaded with human HER-2+ CFPAC-l cells and HLA-A2 matched Jurkat HU are efficiently killed. Also in this case, priming with CCL 16/mDCneu significantly increased the cytotoxic activity.
The higher efficiency with which DC matured in the presence of CCL 16 trigger naive T cells probably rests on its ability to facilitate the cross-presentation ofphagocytosed antigens. Germane to this possibility are our previous data with mouse cells showing that CCL16 very efficiently costimulates macrophage cytotoxic and antigen presenting activities (19) , and is a potent maturation factor for monocyte-derived DC and a regulator ofTh cell differentiation (20) .
It is now becoming widely accepted that both cytotoxic CD8+ T cells and CD4+ Th cells are critical for the generation and maintenance of potent antitumor responses in vivo (28) (29) (30) . In this context, the present finding that DC loaded with xenogeneic apoptotic tumor cells are equally able to induce Th and cytotoxic responses strongly argues in favor of this vaccination strategy. These data further support the notion that vaccination with autologous DC matured in the presence of CCL16 and loaded with xenogeneic tumor antigens should be evaluated as a fresh therapeutic strategy to break tolerance against self tumor antigens.
